User login
TOPLINE:
METHODOLOGY:
- The fungal scalp infection tinea capitis affects an estimated 3%-13% of children.
- While international guidelines exist for the treatment of tinea capitis in infants and children, no such document has been developed in the United States.
- Researchers distributed a survey by email to dermatologists through the and the Society for Pediatric Dermatology in the United States, asking about how they treated and managed pediatric patients with tinea capitis; 56 dermatologists participated.
TAKEAWAY:
- Most respondents (88.2%) said they felt comfortable prescribing oral medications prior to confirmation for those aged 2-18 years ( was the most common choice in 60.4% of cases), compared with 81.6% for those aged 2 months to 2 years ( was the most common treatment choice in 41.5% of cases), and 48.7% for those aged 0-2 months ( was the most common choice in 28.6% of cases).
- When asked what topical medication they would start prior to confirmation, most respondents said shampoo (62.3% for those aged 0-2 months and 75.5% each for those aged 2 months to 2 years and those aged 2-18 years), yet between 11.3% and 13% said they would use none.
- The most common form of confirmatory testing was , followed by potassium hydroxide preparation, trichoscopy, and Wood’s lamp.
- More than half of survey respondents would alter their choice of oral medication based on culture results, but most would not change their topical medication preference.
IN PRACTICE:
“The management of tinea capitis in the United States is currently variable, particularly with the introduction of newer antifungals,” the authors wrote. “Future steps involve establishing evidence-based clinical practice guidelines that consider drug efficacy, safety profiles, and costs.”
SOURCE:
Bernard Cohen, MD, of the Departments of Pediatrics and Dermatology at Johns Hopkins University, Baltimore, Maryland, led the research, which was published in Pediatric Dermatology.
LIMITATIONS:
Lower response rates associated with online surveys and predefined age groups restrict the granularity of responses.
DISCLOSURES:
The authors reported having no financial disclosures.
A version of this article appeared on Medscape.com.
TOPLINE:
METHODOLOGY:
- The fungal scalp infection tinea capitis affects an estimated 3%-13% of children.
- While international guidelines exist for the treatment of tinea capitis in infants and children, no such document has been developed in the United States.
- Researchers distributed a survey by email to dermatologists through the and the Society for Pediatric Dermatology in the United States, asking about how they treated and managed pediatric patients with tinea capitis; 56 dermatologists participated.
TAKEAWAY:
- Most respondents (88.2%) said they felt comfortable prescribing oral medications prior to confirmation for those aged 2-18 years ( was the most common choice in 60.4% of cases), compared with 81.6% for those aged 2 months to 2 years ( was the most common treatment choice in 41.5% of cases), and 48.7% for those aged 0-2 months ( was the most common choice in 28.6% of cases).
- When asked what topical medication they would start prior to confirmation, most respondents said shampoo (62.3% for those aged 0-2 months and 75.5% each for those aged 2 months to 2 years and those aged 2-18 years), yet between 11.3% and 13% said they would use none.
- The most common form of confirmatory testing was , followed by potassium hydroxide preparation, trichoscopy, and Wood’s lamp.
- More than half of survey respondents would alter their choice of oral medication based on culture results, but most would not change their topical medication preference.
IN PRACTICE:
“The management of tinea capitis in the United States is currently variable, particularly with the introduction of newer antifungals,” the authors wrote. “Future steps involve establishing evidence-based clinical practice guidelines that consider drug efficacy, safety profiles, and costs.”
SOURCE:
Bernard Cohen, MD, of the Departments of Pediatrics and Dermatology at Johns Hopkins University, Baltimore, Maryland, led the research, which was published in Pediatric Dermatology.
LIMITATIONS:
Lower response rates associated with online surveys and predefined age groups restrict the granularity of responses.
DISCLOSURES:
The authors reported having no financial disclosures.
A version of this article appeared on Medscape.com.
TOPLINE:
METHODOLOGY:
- The fungal scalp infection tinea capitis affects an estimated 3%-13% of children.
- While international guidelines exist for the treatment of tinea capitis in infants and children, no such document has been developed in the United States.
- Researchers distributed a survey by email to dermatologists through the and the Society for Pediatric Dermatology in the United States, asking about how they treated and managed pediatric patients with tinea capitis; 56 dermatologists participated.
TAKEAWAY:
- Most respondents (88.2%) said they felt comfortable prescribing oral medications prior to confirmation for those aged 2-18 years ( was the most common choice in 60.4% of cases), compared with 81.6% for those aged 2 months to 2 years ( was the most common treatment choice in 41.5% of cases), and 48.7% for those aged 0-2 months ( was the most common choice in 28.6% of cases).
- When asked what topical medication they would start prior to confirmation, most respondents said shampoo (62.3% for those aged 0-2 months and 75.5% each for those aged 2 months to 2 years and those aged 2-18 years), yet between 11.3% and 13% said they would use none.
- The most common form of confirmatory testing was , followed by potassium hydroxide preparation, trichoscopy, and Wood’s lamp.
- More than half of survey respondents would alter their choice of oral medication based on culture results, but most would not change their topical medication preference.
IN PRACTICE:
“The management of tinea capitis in the United States is currently variable, particularly with the introduction of newer antifungals,” the authors wrote. “Future steps involve establishing evidence-based clinical practice guidelines that consider drug efficacy, safety profiles, and costs.”
SOURCE:
Bernard Cohen, MD, of the Departments of Pediatrics and Dermatology at Johns Hopkins University, Baltimore, Maryland, led the research, which was published in Pediatric Dermatology.
LIMITATIONS:
Lower response rates associated with online surveys and predefined age groups restrict the granularity of responses.
DISCLOSURES:
The authors reported having no financial disclosures.
A version of this article appeared on Medscape.com.